Abstract
Background
This study aimed to identify and evaluate potential molecular targets associated with the development of proliferative diabetic retinopathy (DR).
Methods
The microarray dataset “GSE60436” generated from fibrovascular membranes (FVMs) associated with proliferative DR was downloaded from the Gene Expression Omnibus database. Differentially expressed genes (DEGs) from the active FVMs and control or inactive FVMs and control were evaluated and co-DEGs were identified using VEEN analysis. Functional enrichment analysis, and protein-protein interactions (PPI) network and module analyses were performed on the upregulated and downregulated coDEGs. Finally, several predictions regarding microRNAs (miRNAs) and transcription factors (TFs) were made to construct a putative TF-miRNA-target network.
Results
A total of 1475 co-DEGs were screened in active/inactive FVM samples, including 461 upregulated and 1014 downregulated genes, which were enriched for angiogenesis [Hypoxia Inducible Factor 1 Subunit Alpha (HIF1A) and Placental Growth Factor (PGF)] and visual perception, respectively. In the case of the upregulated co-DEGs, Kinesin Family Member 11 (KIF11), and BUB1 Mitotic Checkpoint Serine/Threonine Kinase (BUB1) exhibited the highest values in both the PPI network and module analyses, as well as the genes related to mitosis. In the case of downregulated co-DEGs, several G protein subunits, including G Protein Subunit Beta 3 (GNB3), exhibited the highest values in both the PPI network and module analyses. The genes identified in the module analysis were found to be from the signal transduction-related pathways. In addition, we were able to identify four miRNAs and five TFs, including miR-136 and miR-374.
Conclusions
In brief, HIF1A, PGF, KIF11, G protein subunits, and miR-136, miR-374 may all be involved in angiogenesis, retinal endothelial cell proliferation, and visual signal transduction in proliferative DR. This study provides a number of novel insights that may aid the development of future studies dedicated to discovering novel therapeutic targets in proliferative DR.
Keywords: Proliferative diabetic retinopathy, Differentially expressed gene, Functional enrichment analysis, microRNA, Angiogenesis
Background
Diabetic retinopathy (DR) is one of the most common microvascular complications in diabetes mellitus, and a primary cause of blindness and visual disturbance globally [1]. DR can be divided into non-proliferative and proliferative forms based on the type of microvascular lesions and related ischemic injury [2]. It has been predicted that the global prevalence of diabetes will continue to grow significantly for the next several decades, as a result of increasing incidence of type 1 diabetes rather than increasing type 2 diabetes which has already reached an epidemic level [3]. The incidence of DR increases with diabetic progression and results from a complex process with various molecular and biochemical participants, including oxidative stress, endoplasmic reticulum stress and mitochondrial damage amongst others [4]. The basic mechanisms underlying DR have been extensively studied, however, effective prevention and therapeutic interventions for this disease are still not available.
At present, DR treatments mainly focus on laser photocoagulation, intravitreal pharmacotherapy, anti-VEGF, and glycemic control [5]. Intravitreal anti-inflammatory agents have been effective in treating DR [6], and intravitreal triamcinolone acetonide shows an antiangiogenic effect toward proliferative DR [7]. Vascular endothelial growth factor (VEGF) plays a critical role in promoting vascular permeability, cell migration as well as proliferation of vascular endothelial cells, vasculogenesis, and angiogenesis [8]. VEGF is intimately involved with the progression of proliferative DR and diabetic macular edema facilitating changes in retinal capillary permeability, and advances in anti-VEGF therapies, in age-related macular degeneration, have accelerated the application of anti-VEGF therapies in DR [9]. Oxidative stress is a critical factor in the etiology of DR. Metabolic abnormalities, caused by the increase of glucose concentration in diabetes, can lead to the overproduction of the superoxide radical involved in the uncoupling of mitochondrial electron transport chains, ultimately resulting in oxidative stress [10, 11]. Antioxidants, including Vitamins and polyphenols, are considered a beneficial therapeutic strategy during the treatment of DR. These compounds inhibit the reactive oxygen species, free radicals and enhance the antioxidant defense system [12]. Despite some progress, DR remains a prevalent vision-threatening disease.
In this study, we used the microarray dataset “GSE60436” generated by Ishikawa K et al., [13]. In that study, they identified a subset of differentially expressed genes (DEGs) from active fibrovascular membranes (FVMs) and normal retinas or inactive FVMs and normal retinas, these DEGs were then evaluated by functional analysis. In our study, we aim to identify pivotal genes associated with the pathogenesis of proliferative DR and explore their function and upstream and downstream targets. The common DEGs from active/ inactive FVMs and normal retinas were identified, and then subjected to functional enrichment, protein-protein interaction (PPI) network and module analyses. In addition, the miRNA-target and transcription factors (TFs)-target were predicted to explore the potential regulatory relationships.
Methods
Study approval
This study did not use any animal or human participants. All data was generated from public databases.
Data collection and preprocessing
The gene expression profiling microarray dataset “GSE60436” from FVMs associated with proliferative DR was downloaded from the Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/) database. This dataset was made up of a total of nine samples, including three normal human retinas samples (control), three active FVMs samples (age 57.3 ± 2.1 years; male: female, 1:2; duration of type 2 diabetes, 15.7 ± 2.1 years; glycosylated hemoglobin, 8.3%; vitreous hemorrhage, 1; tractional retinal detachment, 2; no anterior chamber neovascularization; no previous anti-VEGF treatment) and three inactive FVM samples (age 48.0 ± 13 years; male: female, 1:2; duration of type 2 diabetes, 12.3 ± 2.5 years; glycosylated hemoglobin, 6.1%; tractional retinal detachment; no anterior chamber neovascularization; no previous anti-VEGF treatment), with sequencing data generated using the GPL6884 Illumina HumanWG-6 v3.0 expression beadchip.
Limma package software (Version 3.10.3, http://www.bioconductor.org/packages/2.9/bioc/html/limma.html) was used to process the raw CEL files downloaded from GEO, and data preprocessing was done using the RMA (robust multi-array average) method including background correction, normalization, and expression calculations. The probes were removed when they were not able to be matched to a specific gene symbol, and the average value was taken as the expression value for each gene when different probes matched to the same gene symbol.
DEG screening
The genes that were differentially expressed in different groups [active-FVMs vs. control (active group); inactive-FVMs vs. control (inactive group)] were analyzed using the empirical Bayes test from the limma package software [14]. The DEGs were screened using a cut-off value of P < 0.05 and |log fold change (FC)| > 2. The DEGs from both groups were then subjected to VEEN analysis using the VENNY (Version 2.1.0, http://bioinfogp.cnb.csic.es/tools/venny/index.html) online tool. Overlapping genes were considered co-regulated DEGs (co-DEGs) in the following analyses.
Functional enrichment analysis
The Database for Annotation, Visualization and Integrated Discovery (DAVID, Version 6.8, https://david-d.ncifcrf.gov/) online tool was used to analyze the KEGG pathway and Gene Ontology annotations for the co-DEGs. The number of enriched genes was set as: count ≥2, and P < 0.05 was considered the threshold value for significantly enriched terms.
PPI network and module analysis
Search Tool for the Retrieval of Interacting Genes (STRING, Version 11.0, http://www.string-db.org/) was used to predicted the interactions among the co-DEGs with the parameters set to species = human, and PPI score = 0.9 (highest confidence). The PPI network was constructed using Cytoscape software (version 3.2.0, http://www.cytoscape.org/) based on the interactions retrieved from STRING. In addition, the MCODE plugin [15] (Version 1.4.2, http://apps.cytoscape.org/apps/MCODE) from Cytoscape was used to identify the significant modules, with scores > 10, and was followed by functional enrichment analysis.
TF-miRNA-target network construction
The overrepresentation enrichment analysis method from WebGestalt [16] (http://www.webgestalt.org/) was used to predict the TF- and miRNA-target interactions for all of the genes from the significant modules using a cut-off value of P < 0.05. Then, the TF-miRNA-Target regulatory network was constructed by combining miRNA-target and TF-target regulatory interactions.
Results
Data preprocessing and DEG screening
The expression values for all the genes from the nine samples were normalized using the RMA method, and values with an unchanged position in the boxplot were used for subsequent analysis, as this can be used as a proxy for normalization (Fig. 1a). A total of 2025 DEGs were identified in the active group, including 758 upregulated DEGs and 1297 downregulated DEGs. Similarly, 1961 DEGs (757 upregulated and 1204 downregulated) were identified in the inactive group. Fig. 1b shows the heat maps of those DEGs, and reveals that the DEGs can be easily distinguished from each of the samples. In addition, the VEEN analysis, which was performed to identify common DEGs in the two groups, identified 1475 overlapping or co-DEGs. Of these 461 genes were upregulated, and 1014 genes were downregulated (Fig. 1c).
Fig. 1.
Data normalization and the distribution of differentially expressed genes. a, Box plots illustrating data normalization. b, Heat maps of DEGs in active and inactive groups. The horizontal axis represents each sample, and the left vertical axis shows clusters of DEGs. The gradual change of color from green to red represents changes in the expression values from low to high. c, Venn diagram of DEGs in the two groups. DEGs, differentially expressed genes
Functional enrichment analysis
The upregulated co-DEGs were significantly enriched for 148 GO-biological processes (GO-BP) and 41 KEGG pathways. Including “GO:0030198~extracellular matrix organization”, “GO:0001525~angiogenesis” and pathways “hsa04512: ECM-receptor interaction”, “hsa04151: PI3K-Akt signaling pathway”. In addition, the downregulated co-DEGs were significantly enriched for 150 GO-BP terms and 40 KEGG pathways including, “GO:0007601~visual perception”, “GO:0001523~retinoid metabolic process” and pathways “hsa04744: Phototransduction” and “hsa04724: Glutamatergic synapse”. Table 1 summarizes the top 10 GO-BP terms and KEGG pathways.
Table 1.
The top 10 significantly enriched KEGG pathways and GO-BP terms of co-DEGs
| (a) Up-regulated co-DEGs | |||
| Category | Terms | P value | Genes |
| GO_BP | GO:0030198~extracellular matrix organization | 1.10E-19 | PXDN, TNF, LUM, TNC, COL3A1... |
| GO_BP | GO:0006954~inflammatory response | 9.11E-14 | C3AR1, CCL3, TNF, NMI, TLR1... |
| GO_BP | GO:0007155~cell adhesion | 4.44E-12 | TNC, ITGA11, POSTN, IL32, CXCR3... |
| GO_BP | GO:0006955~immune response | 3.50E-09 | PXDN, CCL3, TNF, TLR1, CXCL9... |
| GO_BP | GO:0001525~angiogenesis | 1.37E-08 | PIK3CG, COL4A2,PGF, HIF1A, PIK3CA... |
| GO_BP | GO:0030574~collagen catabolic process | 3.59E-08 | COL4A2, COL4A1, MMP9, COL3A1, COL6A3... |
| GO_BP | GO:0030199~collagen fibril organization | 4.34E-08 | LUM, COL3A1, COL1A2, COL1A1, LOX... |
| GO_BP | GO:0071347~cellular response to interleukin-1 | 1.04E-06 | ADAMTS7, CCL3, HIF1A, PTGIS, CCL3L1... |
| GO_BP | GO:0045766~positive regulation of angiogenesis | 2.34E-06 | C3AR1, CYBB, HIF1A, PTGIS, PGF... |
| GO_BP | GO:0050900~leukocyte migration | 4.37E-06 | C3AR1, OLR1, MMP9, F2RL1, ITGA4... |
| KEGG_pathway | hsa04512:ECM-receptor interaction | 6.58E-17 | COL4A2, COL4A1, COL3A1, ITGA11, ITGA1... |
| KEGG_pathway | hsa04510:Focal adhesion | 1.43E-12 | PGF, TNC, COL3A1, ITGA11, PIK3CA... |
| KEGG_pathway | hsa04151:PI3K-Akt signaling pathway | 3.94E-11 | PGF, OSMR, PIK3CA, COL3A1, ITGA11... |
| KEGG_pathway | hsa04060:Cytokine-cytokine receptor interaction | 1.04E-08 | CCL3, TNF, TNFSF4, TNFRSF12A, OSMR... |
| KEGG_pathway | hsa05146:Amoebiasis | 5.63E-08 | PIK3CG, COL4A2, TNF, COL4A1, COL3A1... |
| KEGG_pathway | hsa04620:Toll-like receptor signaling pathway | 4.16E-07 | PIK3CG, IKBKE, CCL3, TNF, CCL3L1... |
| KEGG_pathway | hsa05222:Small cell lung cancer | 1.96E-06 | PIK3CG, E2F2, COL4A2, LAMA4, COL4A1... |
| KEGG_pathway | hsa05162:Measles | 5.63E-06 | PIK3CG, CD3G, FASLG, CDK6, TLR7... |
| KEGG_pathway | hsa04640:Hematopoietic cell lineage | 1.71E-05 | TNF, CD3G, CD36, ITGA5, FCGR1A... |
| KEGG_pathway | hsa05205:Proteoglycans in cancer | 2.71E-05 | PIK3CG, TNF, LUM, MMP9, ITGA2... |
| (b) Down-regulated co-DEGs | |||
| GO_BP | GO:0007601~visual perception | 5.92E-40 | SLC45A2, PITPNA, MYO7A, RRH, RP1L1... |
| GO_BP | GO:0001523~retinoid metabolic process | 6.62E-11 | RBP4, OPN1LW, RBP1, RBP3, OPN1MW... |
| GO_BP | GO:0006810~transport | 7.57E-11 | RBP7, CRABP1, GABRB3, GRIK1, RBP1... |
| GO_BP | GO:0007602~phototransduction | 4.43E-10 | GUCA1B, UNC119, GUCA1A, TRPC3, OPN1LW... |
| GO_BP | GO:0042462~eye photoreceptor cell development | 7.94E-10 | GNAT1, TULP1, CRB1, FSCN2, MYO7A... |
| GO_BP | GO:0050896~response to stimulus | 8.03E-10 | SLC45A2, CLDN19, IRX5, SLC24A5, RPGRIP1... |
| GO_BP | GO:0070588~calcium ion transmembrane transport | 4.64E-08 | TRPM3, SLC8A2, TRPC3, CACNG7, SLC24A5... |
| GO_BP | GO:0034220~ion transmembrane transport | 1.57E-07 | FXYD3, ATP1B1, GRIK1, GABRB3, ATP1B2... |
| GO_BP | GO:0022400~regulation of rhodopsin mediated signaling pathway | 2.34E-07 | GUCA1B, GNAT1, PDE6A, GUCA1A, PDE6B... |
| GO_BP | GO:0042572~retinol metabolic process | 3.37E-07 | RDH12, RDH8, ALDH1A2, TTR, RBP4... |
| KEGG_pathway | hsa04744:Phototransduction | 3.68E-10 | GNAT1, GUCA1B, GUCA1A, GUCA1C, CNGB1... |
| KEGG_pathway | hsa04724:Glutamatergic synapse | 7.66E-08 | SLC38A3, GNAO1, GRIK1, ADCY5, GNG13... |
| KEGG_pathway | hsa04727:GABAergic synapse | 1.03E-07 | GABRG2, GABARAPL1, SLC38A3, GNAO1, GABRB3... |
| KEGG_pathway | hsa00350:Tyrosine metabolism | 1.48E-07 | DCT, DDC, TYRP1, TYR, PNMT... |
| KEGG_pathway | hsa04723:Retrograde endocannabinoid signaling | 1.36E-06 | GABRG2, GNAO1, GABRB3, ADCY5, GABRB1... |
| KEGG_pathway | hsa04721:Synaptic vesicle cycle | 1.37E-05 | CPLX4, SLC17A7, SLC32A1, ATP6V1C2, SLC17A8... |
| KEGG_pathway | hsa04261:Adrenergic signaling in cardiomyocytes | 2.72E-05 | ATP1B1, ATP1B2, MYL3, TNNC1, ADCY5... |
| KEGG_pathway | hsa05033:Nicotine addiction | 4.19E-05 | SLC17A7, SLC32A1, SLC17A8, GABRG2, GABRR1... |
| KEGG_pathway | hsa04020:Calcium signaling pathway | 9.36E-05 | PTGER1, SLC8A2, SLC25A4, CCKBR, TNNC1... |
| KEGG_pathway | hsa04725:Cholinergic synapse | 3.05E-04 | GNAO1, ADCY5, GNG13, KCNJ14, GNG8... |
PPI network and module analysis
For the upregulated co-DEGs.
The upregulated co-DEGs were used to retrieve various predicted interactions, which were then used to create the PPI network. This network consisted of 202 nodes and 751 interactions (Supplemental Fig. 1). Moreover, two significant modules with score ≥ 10 were identified. Module-A (score = 18.4) contained 21 nodes and 184 interactions, and module-B (score = 12) included 12 nodes and 66 interactions (Fig. 2). Kinesin Family Member 11 (KIF11), BUB1 Mitotic Checkpoint Serine/Threonine Kinase (BUB1) and Cyclin B2 (CCNB2) were the hub genes with the highest degree of relevance in both the PPI network and module-A. The genes in module-A were found to be related to three KEGG pathways and 25 GO-BP terms, including “GO:0007067~mitotic nuclear division” and “GO:0051301~cell division”. Additionally, the genes in module-B were found to participated in three KEGG pathways and eight GO-BP terms, including “GO:0030198~extracellular matrix organization”.
Fig. 2.
The significant modules identified in the PPI network of upregulated co-DEGs. Node size represents the degree score; lines represent interactions; co-DEGs, co-regulated differentially expressed genes
For the downregulated co-DEGs.
The PPI network constructed using downregulated co-DEGs contained 349 nodes and 870 interactions (Supplemental Fig. 2), from which two significant modules with score ≥ 10 were also identified. Module-A (score = 18.24) contained 26 nodes and 228 interactions and module-B (score = 10) included 10 nodes and 45 interactions (Fig. 3). G protein subunits were the hub genes with the highest degree of conservation in both the PPI network and module-A, including G Protein Subunit Beta 3 (GNB3), GNB5, G Protein Subunit Gamma 13 (GNG13), GNG8, GNG17, and GNG3. The genes in module-A were found to be significant in 16 KEGG pathways and 34 GO-BP terms, including “hsa04725: Cholinergic synapse” and “GO:0007186~G−protein coupled receptor signaling pathway”. Similarly, the genes in module-B were found to be associated with two KEGG pathways and nine GO-BP terms. Fig. 4 shows the enriched KEGG pathways and top five GO-BP terms for the genes found in the significant modules.
Fig. 3.
The significant modules identified in the PPI network of downregulated co-DEGs. Node size represents the degree score; lines represent interactions. co-DEGs, co-regulated differentially expressed genes
Fig. 4.
Functional enrichment analysis of the genes found in the significant modules. a, top five enriched GO-BP terms b, enriched KEGG pathways. The gradual change of color from red to green represents the transition of p-values from high to low while bubble size indicates the number of genes enriched in each of the corresponding pathways
TF-miRNA-target network construction
The genes from the significant modules were used to predicted the TF- and miRNA-target interactions, which were then used to construct the TF-miRNA-target network (Fig. 5). The TF-miRNA-target network consisted of 33 nodes and 27 interactions, from which we were able to identify four miRNAs and five TFs, which may interact with up to 24 novel genes. GNG3 was shown to be regulated by miR-136, and Growth Factor Independent 1 Transcriptional Repressor (GFI1). KIF20A was regulated by miR-374, and so on.
Fig. 5.
TF-miRNA-Target regulatory network. Blue triangles represent the miRNA; orange hexagons represent TFs; pink circles represent the upregulated genes and green rhombi represent the downregulated genes
Discussion
In this study, we identified 1475 co-DEGs from active/inactive-FVMs samples. The upregulated co-DEGs were found to participate in angiogenesis [Hypoxia Inducible Factor 1 Subunit Alpha (HIF1A) and Placental Growth Factor (PGF)] and mitosis-related processes (the genes in upregulated module-A, including KIF11 and BUB1). The downregulated co-DEGs were enriched in G − protein coupled receptor signaling and other pathways (The genes in downregulated module-A, including GNB3 and GNG8).
The important pathological features of proliferative DR including abnormal growth of retinal blood vessels and angiogenesis have all been linked to VEGF signaling. High blood sugar can trigger hypoxia in retinal tissues, and this hypoxia acts as a crucial factor in the regulation of VEGF-induced angiogenesis through the production of HIF [17]. HIF1A is an hypoxia induced TF and the lack of HIF1A suppresses the formation of the retinal intermediate vascular plexus in mouse models [18]. PGF, a homologue of VEGF, plays an important role in placental development, and has been shown to be involved in pathological angiogenesis both in ocular and non-ocular cancers [19]. In addition, increased expression of PGF has also been observed in the vitreous of DR patients [19]. Bender et al., revealed that PGF and VEGFA are both essential for follicular angiogenesis in primates, and neither can function alone and result in normal follicular angiogenesis [20]. Huang et al. showed that PGF negatively effects retinal endothelial cell barrier function by activating VEGFR1 and VEGFR2 and inhibiting glucose-6-phosphate dehydrogenase and the antioxidant pathways [21]. Ishikawa K et al., reported that the genes that were significantly upregulated in active FVMs were predominantly part of the angiogenesis process [13]. Therefore, we speculate that PGF and VEGF are important in the progression of FVM to proliferative DR.
MicroRNAs (miRNAs) are small non-coding RNAs of around 22 nucleotides (nt) in length, which mediate the expression of protein-coding genes, and are becoming increasingly popular biomarkers used in both prognostic and diagnostic assays [22, 23]. Targets for miR-136 and miR-374 were significantly enriched in the co-DEGs identified in this study. However, the relationship between miR-136 or miR-374 and DR is not well reported, and this is the first publication linking them. miR-136 is highly expressed in pre-eclampsia and inhibits the formation of HUVEC capillaries via dysregulation of VEGF. In addition, the expression levels of miR-136 inversely correlates with VEGF [24]. In paclitaxel-resistant ovarian cancer cells, pre-miR-136 transfection significantly decreased angiogenesis and induced apoptosis, and regulation of miR-136 expression could re-sensitize paclitaxel-resistant cells [25]. C-C Motif Chemokine Ligand 3 represses the expression of miR-374b, which subsequently accelerates VEGF-A level and angiogenesis in osteosarcoma cells [26]. Thus, we speculate that miR-136 and miR-374 may participate in the regulation of angiogenesis in proliferative DR.
KIF11 is a member of the kinesin-like protein family. Mutations in KIF11 have been shown to cause familial exudative vitreoretinopathy associated with retinal detachment [27]. Birtel et al., revealed that KIF11 is important in both ocular development and the maintenance of retinal morphology and function and defects in this protein have been associated with retinal ciliopathy [28]. KIFs are motor proteins involved in the activities of the centrosome and spindle during mitosis. In our study, KIFs (KIF11, KIF15, KIF20A) and other mitosis-associated genes, like BUB1, were significantly enriched in one module involved in cell division and mitotic nuclear division. The proliferation of retinal endothelial cells is a significant event in the progression of DR [29]. In addition, a previous study has shown that high glucose significantly increases the proliferation of retinal endothelial cells and the expression levels of VEGF, also, it was more effective under intermittent high glucose, than constant high glucose conditions [30]. Therefore, we suggest that the genes in this module play a key role in proliferative DR through the regulation of the proliferation of retinal endothelial cells.
G proteins are a kind of heterotrimeric guanine nucleotide-binding protein consisting of three subunits (alpha, beta and gamma subunits), which play an important role in intracellular signal transduction, including insulin, epinephrine, dopamine signaling molecule transduction [31]. GNB3 encodes G Protein Subunit Beta 3. The GNB3 gene polymorphisms, including C825T, have been linked to type 2 diabetes mellitus and its complications [32]. GNB3 knockout lead to the malfunction of cone photoreceptors and ON-bipolar cells in murine retinas [33]. In addition, it was revealed that a naturally occurring mutation in GNB3 results in retinal degeneration in chickens [34]. A homozygous missense variant in GNB3 results in a unique stationary retinal disorder with dual anomalies in visual processing, night blindness and photophobia [35]. G protein subunits (GNB3, GNB5, GNG3, GNG7, GNG8, GNG13) are downregulated in proliferative DR, and significantly enriched in module A which is associated with cellular responses to glucagon stimuli including G − protein coupled receptor signaling pathways and other biological processes. Therefore, we conclude that G proteins may play a crucial role in visual signal transduction in proliferative DR.
Although this study has made several novel observations, all the results were based on bioinformatics analysis, and further experimental verification is required. In addition, in an ideal situation, healthy retinas, non-proliferative diabetic retinas and autologous retinas should be used as controls for a more comprehensive comparison with retinas from subjects with FVM-associated proliferative DR. However, such microarray studies are limited by challenges in obtaining samples. Additionally, the small sample size in this study may also limit the application of our observations. Genes that are important for proliferative DR might be excluded as a result of the small sample size and inter-sample variation.
Conclusions
In brief, we investigated differentially expressed gene profiles in proliferative DR. Several genes, including HIF1A, PGF, KIF11, G protein subunits, and miR-136, miR-374 were found to be involved in angiogenesis, retinal endothelial cell proliferation, and visual signal transduction in proliferative DR. These findings could provide valuable insight and foundations for the study of proliferative DR’s pathomechanism and may provide an idea of potential therapeutic targets for its treatment.
Supplementary information
Additional file 1 Figure S1 The PPI network of upregulated co-DEGs. Node size represents the degree score; lines represent interactions; co-DEGs, co-regulated differentially expressed genes.
Additional file 2 Figure S2. The PPI network of downregulated co-DEGs. Node size represents the degree score; lines represent interactions; co-DEGs, co-regulated differentially expressed genes.
Acknowledgements
Not applicable.
Abbreviations
- DR
Diabetic retinopathy
- FVMs
Fibrovascular membranes
- DEGs
Differentially expressed genes
- PPI
Protein-protein interactions
- miRNAs
Micrornas
- TFs
Transcription factors
- HIF1A
Hypoxia Inducible factor 1 subunit alpha
- PGF
Placental growth factor
- KIF11
Kinesin family member 11
- BUB1
BUB1 mitotic checkpoint serine/threonine kinase
- GNB3
G Protein Subunit Beta 3
- VEGF
Vascular endothelial growth factors
- co-DEGs
Co-regulated DEGs
- GO-BP
GO-biological processes
- KIF11
Kinesin family member 11
- CCNB2
Cyclin B2
- GNG13
G protein subunit gamma 13
- GFI1
Growth factor independent 1 transcriptional repressor
Authors’ contributions
Conceptualization and manuscript preparation were completed by DWS, XQZ and ZHL. Acquisition of data was completed by ZY. Analysis and interpretation of data was completed by DWS. Statistical analysis was done by WS and TJM. Revision of manuscript for important intellectual content was undertaken by SZH and WF. All authors have read and approved the manuscript in its current state.
Funding
This work was supported by the National Natural Science Foundation of China (No. 81870640) and the Beijing Natural Science Foundation (No. 7182152). The funders play the roles of collection, analysis, and interpretation of data.
Availability of data and materials
The dataset “GSE60436” were downloaded from GEO data NCBI Gene Expression Omnibus repository. All the data of the current study are available at https://pan.baidu.com/s/12j9WMgvoBapXW3WGCSGfhQ, and the extraction code can be obtained from the corresponding author upon reasonable request.
Ethics approval and consent to participate
This study was approved by the Ethics Committee from The Chinese People’s Liberation Army General Hospital and Air Force Medical Center.
Consent for publication
Not applicable.
Competing interests
The authors have no conflicts of interest to declare.
Footnotes
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Contributor Information
Dewang Shao, Email: dewangshao@sina.com.
Shouzhi He, Email: heshouzhi@sina.com.
Zi Ye, Email: yeziclover@163.com.
Xiaoquan Zhu, Email: zhuxiaoquan2019@sina.com.
Wei Sun, Email: Weisun2019@126.com.
Wei Fu, Email: Weifu2019@126.com.
Tianju Ma, Email: afree_8341@163.com.
Zhaohui Li, Email: zhaohuili650@hotmail.com.
Supplementary information
Supplementary information accompanies this paper at 10.1186/s12886-020-01381-5.
References
- 1.Laud K, Shabto U, Tello C: Diabetic Retinopathy. In: Principles of Diabetes Mellitus. edn. Edited by Poretsky L. Cham: Springer International Publishing; 2016:1–18.
- 2.Stitt AW, Curtis TM, Chen M, Medina RJ, Mckay GJ, Jenkins A, Gardiner TA, Lyons TJ, Hammes HP, Simó R. The progress in understanding and treatment of diabetic retinopathy. Prog Retin Eye Res. 2016;51:156–186. doi: 10.1016/j.preteyeres.2015.08.001. [DOI] [PubMed] [Google Scholar]
- 3.Duh EJ, Sun JK, Stitt AW. Diabetic retinopathy: current understanding, mechanisms, and treatment strategies. Jci Insight. 2017;2(14):e93751. doi: 10.1172/jci.insight.93751. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Petrovski G, Kaarniranta K, Petrovič D. Oxidative stress, epigenetics, environment, and epidemiology of diabetic retinopathy. Journal of Diabetes Research. 2017;2017:6419357. doi: 10.1155/2017/6419357. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Stewart MW. Treatment of diabetic retinopathy: recent advances and unresolved challenges. World J Diabetes. 2016;7(16):333–341. doi: 10.4239/wjd.v7.i16.333. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Kumar B, Gupta SK, Saxena R, Srivastava S. Current trends in the pharmacotherapy of diabetic retinopathy. J Postgrad Med. 2016;58(2):132–9. [DOI] [PubMed]
- 7.Jonas JB. Intravitreal triamcinolone acetonide for diabetic retinopathy. Dev Ophthalmol. 2007;39:96–110. doi: 10.1159/000098502. [DOI] [PubMed] [Google Scholar]
- 8.Gupta N, Mansoor S, Sharma A, Sapkal A, Sheth J, Falatoonzadeh P, Kuppermann B, Kenney M. Diabetic retinopathy and VEGF. Open Ophthalmol J. 2013;7(1):4–10. doi: 10.2174/1874364101307010004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Nicholson BP, Schachat AP. A review of clinical trials of anti-VEGF agents for diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2010;248(7):915–930. doi: 10.1007/s00417-010-1315-z. [DOI] [PubMed] [Google Scholar]
- 10.Calderon GD, Juarez OH, Hernandez GE, Punzo SM, ZDDL C. Oxidative stress and diabetic retinopathy: development and treatment. Eye. 2017;31(8):1122–30. [DOI] [PMC free article] [PubMed]
- 11.Guzman DC, Olguín HJ, García EH, Peraza AV, Dz DLC, Soto MP. Mechanisms involved in the development of diabetic retinopathy induced by oxidative stress. Redox Rep. 2017;22(1):10–16. doi: 10.1080/13510002.2016.1205303. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Li C, Miao X, Li F, Wang S, Liu Q, Wang Y, Sun J. Oxidative Stress-Related Mechanisms and Antioxidant Therapy in Diabetic Retinopathy. Oxid Med Cell Longev. 2017;(11):9702820. [DOI] [PMC free article] [PubMed]
- 13.Keijiro I, Shigeo Y, Yoshiyuki K, Yedi Z, Takahito N, Shintaro N, Yukio S, Yuji O, Hiroaki N, Koichi A. Microarray analysis of gene expression in fibrovascular membranes excised from patients with proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci. 2015;56(2):932. doi: 10.1167/iovs.14-15589. [DOI] [PubMed] [Google Scholar]
- 14.Smyth G.K. (2005) limma: Linear Models for Microarray Data. In: Gentleman R, Carey VJ, Huber W, Irizarry RA, Dudoit S. (eds) Bioinformatics and Computational Biology Solutions Using R and Bioconductor. Statistics for Biology and Health. Springer: New York.
- 15.Bandettini WP, Kellman P, Mancini C, Booker OJ, Vasu S, Leung SW, Wilson JR, Shanbhag SM, Chen MY, Arai AE. MultiContrast delayed enhancement (MCODE) improves detection of subendocardial myocardial infarction by late gadolinium enhancement cardiovascular magnetic resonance: a clinical validation study. J Cardiovasc Magn Reson Official J Soc Cardiovasc Magn Reson. 2012;14(1):83. doi: 10.1186/1532-429X-14-83. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Nucleic Acids Res. 2005, 33(Web Server issue):W741–8. [DOI] [PMC free article] [PubMed]
- 17.Crawford TN, Rd AD, Kerrison JB, Jablon EP. Diabetic retinopathy and angiogenesis. Curr Diabetes Rev. 2009;5(1):8–13. [DOI] [PubMed]
- 18.Christian C, Markus T, Christina L, Sandrine J, Marijana S, Christian G. HIF1A is essential for the development of the intermediate plexus of the retinal vasculature. Invest Ophthalmol Vis Sci. 2011;52(5):2109–2117. doi: 10.1167/iovs.10-6222. [DOI] [PubMed] [Google Scholar]
- 19.Nguyen QD, De FS, Behar-Cohen F, Lam WC, Li X, Reichhart N, Ricci F, Pluim J, Li WW. Placental growth factor and its potential role in diabetic retinopathy and other ocular neovascular diseases. Acta Ophthalmol. 2018;96(1):e1–e9. doi: 10.1111/aos.13325. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Bender HR, Trau HA, Duffy DM. Placental growth factor is required for ovulation, Luteinization, and angiogenesis in primate ovulatory follicles. Endocrinology. 2018;159(2):710–722. doi: 10.1210/en.2017-00739. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Huang H, Lennikov A, Saddala MS, Gozal D, Grab DJ, Khalyfa A, Fan L. Placental growth factor negatively regulates retinal endothelial cell barrier function through suppression of glucose-6-phosphate dehydrogenase and antioxidant defense systems. FASEB J. 2019;33(12):13695–13709. doi: 10.1096/fj.201901353R. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Joglekar MV, Januszewski AS, Jenkins AJ, Hardikar AA. Circulating microRNA biomarkers of diabetic retinopathy. Diabetes. 2016;65(1):22–24. doi: 10.2337/dbi15-0028. [DOI] [PubMed] [Google Scholar]
- 23.Farr RJ, Januszewski AS, Joglekar MV, Liang H, McAulley AK, Hewitt AW, Thomas HE, Loudovaris T, Kay TWH, Jenkins A, et al. A comparative analysis of high-throughput platforms for validation of a circulating microRNA signature in diabetic retinopathy. Sci Rep. 2015;5:10375. doi: 10.1038/srep10375. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Ji L, Zhang L, Li Y, Guo L, Cao N, Bai Z, Song Y, Xu Z, Zhang J, Liu C. MiR-136 contributes to pre-eclampsia through its effects on apoptosis and angiogenesis of mesenchymal stem cells. Placenta. 2017;50:102–109. doi: 10.1016/j.placenta.2017.01.102. [DOI] [PubMed] [Google Scholar]
- 25.An H, Jeong J, Lee M, Song J, Jung Y, Kim Y, Kwon A, Huh J, Kim K, Kang H. 275: MiR-136 targeting Notch3 is involved in chemoresistance and angiogenesis in ovarian cancer cells. Eur J Cancer. 2014;50(1):S65. doi: 10.1016/S0959-8049(14)50244-4. [DOI] [Google Scholar]
- 26.Liao Y-Y, Tsai H-C, Chou P-Y, Wang S-W, Chen H-T, Lin Y-M, Chiang IP, Chang T-M, Hsu S-K, Chou M-C, et al. CCL3 promotes angiogenesis by dysregulation of miR-374b/ VEGF-A axis in human osteosarcoma cells. Oncotarget. 2015;7(4):4310–4325. doi: 10.18632/oncotarget.6708. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Hu H, Xiao X, Li S, Jia X, Guo X, Zhang Q. KIF11 mutations are a common cause of autosomal dominant familial exudative vitreoretinopathy. Br J Ophthalmol. 2016;100(2):278–283. doi: 10.1136/bjophthalmol-2015-306878. [DOI] [PubMed] [Google Scholar]
- 28.Birtel J, Gliem M, Mangold E, Tebbe L, Spier I, Müller PL, Holz FG, Neuhaus C, Wolfrum U, Bolz HJ. Novel insights into the Phenotypical Spectrum of KIF11-associated retinopathy, including a new form of retinal Ciliopathy. Invest Ophthalmol Vis Sci. 2017;58(10):3950. doi: 10.1167/iovs.17-21679. [DOI] [PubMed] [Google Scholar]
- 29.West DC, Kumar S. Endothelial cell proliferation and diabetic retinopathy. Lancet. 1988;331(8587):715–716. doi: 10.1016/S0140-6736(88)91526-7. [DOI] [PubMed] [Google Scholar]
- 30.Sun J, Xu Y, Sun S, Sun Y, Wang X. Intermittent high glucose enhances cell proliferation and VEGF expression in retinal endothelial cells: the role of mitochondrial reactive oxygen species. Mol Cell Biochem. 2010;343(1–2):27–35. doi: 10.1007/s11010-010-0495-5. [DOI] [PubMed] [Google Scholar]
- 31.Gilman AG. G proteins: transducers of receptor-generated signals. Annu Rev Biochem. 1986;56(56):615–649. doi: 10.1146/annurev.bi.56.070187.003151. [DOI] [PubMed] [Google Scholar]
- 32.Rizvi S, Raza ST, Rahman Q, Mahdi F. Role of GNB3 , NET , KCNJ11 , TCF7L2 and GRL genes single nucleotide polymorphism in the risk prediction of type 2 diabetes mellitus. Biotech. 2016;6(2):255. doi: 10.1007/s13205-016-0572-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Arno G, Holder GE, Chakarova C, Kohl S, Pontikos N, Fiorentino A, Plagnol V, Cheetham ME, Hardcastle AJ, Webster AR. Recessive retinopathy consequent on mutant G-protein β subunit 3 (GNB3) Jama Ophthalmol. 2016;134(8):924. doi: 10.1001/jamaophthalmol.2016.1543. [DOI] [PubMed] [Google Scholar]
- 34.Hemanth T, Manir A, Paul G, Hocking PM, Burt DW, Inglehearn CF, Lester DH. Mutation in the guanine nucleotide-binding protein beta-3 causes retinal degeneration and embryonic mortality in chickens. Invest Ophthalmol Vis Sci. 2006;47(11):4714. doi: 10.1167/iovs.06-0292. [DOI] [PubMed] [Google Scholar]
- 35.Banin E, Bocquet B, Debaere E, Casteels I, Defoort-Dhellemmes S, Drumare I, Friedburg C, Gottlob I, Jacobson S, Kellner U. Biallelic mutations in GNB3 cause a unique form of autosomal-recessive congenital stationary night blindness. Am J Hum Genet. 2016;98(5):1011–1019. doi: 10.1016/j.ajhg.2016.03.021. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Additional file 1 Figure S1 The PPI network of upregulated co-DEGs. Node size represents the degree score; lines represent interactions; co-DEGs, co-regulated differentially expressed genes.
Additional file 2 Figure S2. The PPI network of downregulated co-DEGs. Node size represents the degree score; lines represent interactions; co-DEGs, co-regulated differentially expressed genes.
Data Availability Statement
The dataset “GSE60436” were downloaded from GEO data NCBI Gene Expression Omnibus repository. All the data of the current study are available at https://pan.baidu.com/s/12j9WMgvoBapXW3WGCSGfhQ, and the extraction code can be obtained from the corresponding author upon reasonable request.